Summa Health Cancer Institute
2018 Outcomes Report
1
Contents
A message from leadership The Summa Health Cancer Institute has had the privilege of treating thousands of patients who valiantly fight this dreaded disease. Our goal—always— is to make the difficult journey from cancer diagnosis through treatment and survivorship as easy and seamless as possible. In 2018, our cancer services continued to evolve. Highlights from this past year include: • Our Lung Nodule Clinic and Thoracic Multidisciplinary Clinic (MDC) continue to grow. The MDC care delivery model allows patients to receive a coordinated, comprehensive and personalized plan of care using nationally recognized best practice guidelines in one appointment. Its success allowed us to expand our footprint onto both our Akron and Barberton Campuses, serving more patients. • Research continues to play a key role for our patients. Our patients have the opportunity to be included in important research to improve cancer patient survival; our research staff is dedicated to continuously moving cancer care forward. I delivered the keynote address at the American Cancer Society Cancer Action Network in Cleveland on August 8, 2018, to reinforce the importance of clinical trials. • We continue to enhance our survivorship program, finding the best ways to optimize the care and support we provide our patients long-term. • We strengthened our staff by adding several welltrained, nationally recognized doctors to the Institute including medical oncologists Teresa Goebel, D.O. and Nicholas Pleat, D.O. Our providers continue to stand out in their fields and serve as thought leaders, regularly publishing papers in international journals and serving on prestigious committees. • Continuing our focus on patients, we implemented an Urban Zen Integrative Therapy program, designed to change the present healthcare paradigm. This unique program treats the entire patient and not just the disease, and incorporates yoga therapies, Reiki, essential oil therapy, nutrition and contemplative care as part of a patient’s treatment.
Navigating the Oncology Care Model ................................................................... 4 Lung Nodule Navigation ............................................................................................7 2018 Primary Cancer Sites ....................................................................................... 8 2018 Top Five Cancer Sites ...................................................................................... 9 Recognition . .............................................................................................................. 10 Staging & NCCN Guideline Study Summary ...................................................... 12 Cooper Cancer Center Pharmacy Time Study .................................................. 14 Research Update ...................................................................................................... 15 Free Skin Cancer Screening Community Event ................................................ 16 Monitoring of Prevention, Screening and Outreach Activities ........................17 Committee Members ............................................................................................... 18
Our stellar work was recognized by the Commission on Cancer, as they awarded a full, three-year accreditation with commendation (Gold Level Status) to the Summa Health Cancer Institute. In addition, we earned the prestigious American College of Radiation (ACR) accreditation in radiation oncology.
9
And our work continues this year. We are relentless in our pursuit of high quality cancer care for our patients. Our Cancer Institute team remains dedicated to reducing preventable cancers, increasing cancer survival and improving patient experience as well as quality of life, one patient at a time.
12
Gilbert D.A. Padula, M.D. Medical Director Summa Health Cancer Institute
15
16
Navigating the Oncology Care Model Director-Hematology Oncology and Oncology Care Model at Summa Health
Dr. Mahesh published “Value-Based Oncology: Ongoing Lessons From an Oncology Care Model” in Oncology Times in April 2018.
The Center for Medicare and Medicaid Innovation designed the Oncology Care Model (OCM), which allows practices and payers in the United States to collaborate with the Centers for Medicare & Medicaid Services (CMS). The goal of the OCM is to provide high quality, highly coordinated cancer care at the same or lower cost. The OCM is one of the many programs that CMS is promoting to help shift payment models from a fee-for-service arrangement to a value-based approach. Practice partnerships with the CMS involve payment arrangements that include financial and performance accountability for episodes of cancer care surrounding chemotherapy delivery to patients. Currently, there are 173 practices that have entered into agreement with CMS and Summa Health is one of them. Practices that have been selected by the CMS have attested to providing a number of enhanced services from 24/7 patient access to an appropriate clinician who can access medical records to having a documented evidence-based comprehensive care plan for every patient. What are some practice modifications implemented at Summa Health Cancer Institute to ensure success in this population health endeavor? Drugs, hospital, and ED visits, along with imaging and laboratory evaluation, account for 75% of the cost. Some strategies to reduce expenditure involve targeting those areas.
Alternative payment models for cancer care: How did we get here? Care of the cancer patient is complex and expensive. During 2001-2011, medical spending to treat cancer increased from $56.8 billion to $88.3 billion in the United States. During this time, ambulatory expenditures for care and treatment increased while inpatient hospital expenditures decreased. Treatments for cancer have advanced, but costs do not correlate with outcomes. Advanced payment models aimed at ensuring high quality while lowering costs may be the vehicle to help mitigate the financial burden of cancer treatment on patients and society.
Chemotherapy drugs are prescribed resourcefully without impairing outcomes. For instance, bisphosphonates for bone metastasis are given every 12 weeks instead of 4 weeks. Similarly, adjuvant chemotherapy is given for three months, instead of six months in appropriate stage 3 colon cancer patients. Pertuzumab is used judiciously in early-stage breast cancer patients. These are all evidencebased recommendations when adopted systematically limit patient experienced adverse effects in addition to decreasing expenditures. At Summa Health Cancer Institute, we have implemented stringent protocols around how often patients are imaged and tested. PET scans are avoided when clinical decision-making is not affected. We have adopted recommendations from Choosing Wisely campaign like avoiding staging scans in early-stage breast and prostate cancer patients, and surveillance scans among early-stage breast cancer and lymphoma patients since they do not positively affect outcomes.
Another area where quality care meets cost effective care is in the early engagement of palliative care. Several studies have shown that early involvement of palliative care improves survival and quality of life. Palliative care involvement also decreases the emotional burden for patients and oncologists. Appropriate symptom control, particularly pain management decreases hospitalizations during treatment. Palliative care is embedded in our practice and is an integral part of the cancer treatment team. Investing in a robust supportive care team – financial advocates, social work, nutrition, behavioral health, as well as various community services – can help reduce the financial, physical and emotional distress levels for patients. Care teams working at the highest level of competence and license helps meet population health goals. Oncology nurses are integral in implementing triage pathways to assess side effects and symptom management. Patients are triaged for same day visits if required. Oncology infusion centers are used to provide hydration and blood transfusions in a timely fashion thus avoiding ED visits. In June 2018, Summa Health Cancer Institute’s Supportive Care team was recognized by CMS and organized an educational event for other practices in the country.
While the program focuses on Medicare beneficiaries, Summa Health has extended these enhanced services to all of their patients. Cancer patients treated at Summa Heath meet triple aim CMS sends quarterly feedback reports that contain information on practice demographics, outcomes, expenditures, chemotherapy use and patient satisfaction. The outcomes include the mortality rate for Medicare beneficiaries treated at the practice, compared with other practices nationally. In addition, the reports include endof-life metrics and patient satisfaction, as well as details of expenditures on drugs, hospital use, imaging and laboratory services, and a description of chemotherapy usage. These reports are a helpful tool for measuring our utilization of services, as well as benchmarking it against national figures. The 12-month mortality rate for beneficiaries treated at Summa Health in 2018 was 4.3% compared to 4.7% nationally. As seen from the reports below, cancer patients managed at Summa Health Cancer Institute have superior outcomes at a lower cost with highest level of satisfaction. A win for all!
Figure 1: Trends In Total Medicare Expenditures per Beneficiary per Month (Risk Adjusted 4-quarter averages)
$5,500
Dollars
Sameer Mahesh, M.D.
$5,000
$4,500
Jan-Mar 2017
Apr-Jun 2018
Jul-Sep 2018
Oct-Dec 2018
Jan-Mar 2018
Apr-Jun 2018
Jul-Sep 2018
Oct-Dec 2018
Summa Health Median for All Practices Providing Cancer Care Median for OCM Practices
4
Cancer Institute 2018 Outcomes Report
5
Figure 14. OCM Patient Survey. Trends in the average of the overall rating and the composite scores (Excluding Shared Decision-Making) for OCM Practices and Your Practice (Risk Adjusted; Waves 1-9) 8.6
Scores
8.4
8.2
8.0
Waves 1-2
Waves 2-3
Waves 3-4
Waves 4-5
Waves 5-6
Waves 6-7
Waves 7-8
Waves 8-9
Summa Health Median for OCM Practices 10th Percentile for OCM Practices 90th Percentile for OCM Practices
Lung Nodule Navigation Figure 2: Trends in Inpatient Admissions to Short-term Acute Care Hospitals and CAHs All Cause Per 100 Beneficiaries (Not Risk Adjusted; 4-quarter Averages)
Per 100 Beneficiaries
22
Last year we focused many efforts on our Lung Nodule Clinic. The growing use of CT chest imaging has resulted in increased incidental lung nodules findings. A recent study found that between 2006 and 2012, the annual rate of pulmonary nodule identification in a large integrated health system increased from 3.9 to 6.6 per 1,000 person-years. These incidental findings require appropriate management to avoid care gaps that may lead to missed early lung cancer detection or conversely to avoid unnecessary follow-up scans.
20
18
16 Jan-Mar 2017
As we look back over 2018, we continue to see Summa Health Cancer Institute develop and progress the care and support we provide cancer patients. We have the privilege of working with patients to make the difficult journey from cancer diagnosis through treatment and survivorship as easy and seamless as possible. And we take that responsibility seriously. We work collaboratively to improve the outcomes of our patients.
Apr-Jun 2018
Jul-Sep 2018
Oct-Dec 2018
Jan-Mar 2018
Apr-Jun 2018
Jul-Sep 2018
Oct-Dec 2018
In January 2016, a dedicated lung navigator at Summa Health was assigned to the interdisciplinary thoracic team to manage follow-up of incidental lung nodules for emergency patients. During the first year, referrals to the navigator averaged eight patients per month.
The application of an Incidental Lung Nodule Navigation Model of Care and Clinic provides lung navigators with a framework to support patient-centered best practice. A dedicated lung navigator for patients seen in the emergency department who are found to have incidental lung nodules is a member of an interdisciplinary team. This team has a key impact on the timeliness for lung care delivery. Coordinating nodule follow-up care requires consistent and frequent communications, which is possible with the newly opened Lung Nodule Clinic. We know that the time between lung nodule detection to diagnosis is very stressful. Our expedited appointments, continued follow-up and surveillance offer the appropriate options for patients and their lung care. We are firmly committed to offering our patients every significant advantage in their battle against cancer. We are relentless in our pursuit of delivering the best cancer care possible.
Brian Bauman, M.D., FCCP Medical Director, Summa Health Lung Nodule Program Respiratory Care and Pulmonary Service
Summa Health Median for All Practices Providing Cancer Care (All Risk Quantities Combined) Median for OCM Practices (All Risk Quantities Combined)
6
Cancer Institute 2018 Outcomes Report
Over time, referrals to the lung navigator for incidental nodules increased to 52 patients per month. Continued quality improvement strategies and an increasing number of referrals led to the approval of a new Lung Nodule Clinic, which opened in early 2018.
Eric Espinal, M.D., FACC, FACS Chief, Cardiothoracic Surgery Director, Thoracic Oncology
7
Primary Site
2018 Primary Cancer Sites
All Sites
8
Total 1,988
Class
Sex
Analytic
Non-Analytic
Male
Female
1,949
39
782
1,206
Oral Cavity & Pharynx
39
39
0
27
12
Tongue Salivary Glands Floor of Mouth Gum & Other Mouth Nasopharynx Tonsil Oropharynx Hypopharynx Digestive System Esophagus Stomach Small Intestine Colon Rectum/Rectosigmoid Anus/Anal Canal/Anorectum Liver/Intrahepatic Bile Duct Gallbladder Other Biliary Pancreas Retroperitoneum Peritoneum/Omentum/Mesentery Respiratory System Nose, Nasal Cavity & Middle Ear Larynx Lung/Bronchus Bones/Joints Soft Tissue Skin Melanoma Other Non-Epithelial Skin Breast Female Genital System Cervix Uteri Corpus Uteri/Uterus, NOS Ovary Vulva Other Female Genital Organs Male Genital System Prostate Testis Penis Other Male Genital Organs Urinary System Urinary Bladder Kidney/Renal Pelvis Ureter Other Urinary Organs Brain & CNS Brain Cranial Nerves Other Nervous System Endocrine System Thyroid Other Endocrine including Thymus Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Blood & Bone Marrow Leukemia Myeloma Other Blood & Bone Marrow Mesothelioma Unknown Primary
12 3 1 2 1 15 3 2 320 26 23 11 122 45 11 23 5 3 45 3 3 338 3 13 322 7 15 44 39 5 407 236 20 166 39 10 1 141 126 12 2 1 159 80 76 2 1 46 15
12 3 1 2 1 15 3 2 316 26 23 11 122 45 11 23 5 3 44 3 3 335 3 13 319 7 15 40 36 4 405 231 17 164 39 10 1 130 115 12 2 1 150 71 76 2 1 46 15
0 0 0 0 0 0 0 0 4 0 0 0 3 0 0 0 0 0 1 0 0 3 0 0 3 0 0 4 3 1 2 5 3 2 0 0 0 11 11 0 0 0 9 9 0 0 0 0 0
8 2 1 2 1 12 1 0 178 20 14 5 60 28 1 14 3 2 28 3 0 172 3 11 158 4 9 21 20 1 4 0 0 0 0 0 0 141 126 12 2 1 100 58 39 2 1 18 9
4 1 0 0 0 3 2 2 142 6 9 6 62 17 10 9 2 1 17 0 3 166 0 2 164 3 6 23 19 4 403 236 20 166 39 10 1 0 0 0 0 0 59 22 37 0 0 28 6
31
31
0
9
22
44 42
44 42
0 0
11 10
33 32
2
2
0
1
1
84 11 73 70 35 20 15 1 37
84 11 73 69 35 19 15 1 37
0 0 0 1 0 1 0 0 0
47 7 40 34 18 12 4 0 16
37 4 33 36 17 8 11 1 21
Cancer Institute 2018 Outcomes Report
2018 Top Five Cancer Sites Breast – 405 Lung/Bronchus – 319 Corpus Uteri – 164 Colon – 122 Prostate – 115
0
100
200
300
400
500
9
Recognition Accreditations Cancer Program American College of Surgeons Commission on Cancer The American College of Surgeons Commission on Cancer (CoC) awarded a full, three-year accreditation with commendation (Gold Level Status) to the Summa Health Cancer Institute, including the Summa Health Jean and Milton Cooper Pavilion at Summa Health System— Akron Campus, Summa Health Parkview Pavilion at Summa Health System— Barberton Campus and Summa Health Medina Medical Center. CoC accreditation is the hallmark of excellence and ensures that quality standards are consistently met and/or exceeded by cancer care centers across the country.
Medical Oncology The Quality Oncology Practice Initiative Summa Health is one of a few cancer centers in Ohio to meet quality measures for medical oncology from the American Society of Clinical Oncology’s Quality Oncology Practice Initiative (QOPI). QOPI is an oncologist-led, practice-based quality improvement program, whose goal is to promote excellence in cancer care by helping practices create a culture of self-examination and improvement.
Breast Imaging Commission on Cancer Commission on Cancer Outstanding 2017 OUTSTANDING ACHIEVEMENT AWARD Achievement Award Our Cancer Institute received the Commission on Cancer (CoC) Outstanding Achievement Award (OAA). A CoC-accredited cancer program is eligible to earn the Outstanding Achievement Award after completing the accreditation survey and receiving a Performance Report that indicates an accreditation award of “Three-Year with Commendation.” The program must receive commendation ratings for the seven commendation level standards and no deficiencies for the remaining 27 standards. The CoC accredits approximately 1,500 programs and surveys 500 programs a year. This designation was awarded to 16, or 3 percent of CoCaccredited programs that were surveyed nationwide between July 1 and December 31, 2017. ®
Radiation Oncology American College of Radiology Summa Health earned the prestigious American College of Radiation (ACR) accreditation in radiation oncology, demonstrating we have undergone a rigorous review process and meet nationally accepted standards of care. In addition, the Center at Summa Health Parkview Pavilion was designated a Breast Imaging Center of Excellence by the American College of Radiation (ACR).
10
Cancer Institute 2018 Outcomes Report
American College of Radiology The Summa Health Breast Imaging Centers at Summa Health System – Akron and Barberton Campuses were designated a Breast Imaging Center of Excellence (BICOE) by the American College of Radiology (ACR). The BICOE designation is awarded to breast imaging centers that achieve excellence by seeking and earning accreditation in all of the ACR’s voluntary breastimaging accreditation programs and modules, in addition to the mandatory Mammography Accreditation Program.
Membership
Publications
NRG Oncology
Regine WF, Winter K, Abrams RA, Safran H, Kessel KL, Chen Y, Fugazzi J, Donnelly ED, Dipetrillo TA, Narayan S, Plastaras JP, Gaur R, Delouya G, Suh JH, Meyer J, Haddock MG, Didolkar MS, Padula GDA, Johnson D, Hoffman JP, Crane C. Postresection CA 19-9 level and surgical margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG Oncology RTOG trial 9704. Advances in Radiation Oncology. 2018 April-June:3(2): 154-162
NRG Oncology is a non-profit research organization formed to conduct oncologic clinical research and to broadly disseminate study results for informing clinical decision-making and healthcare policy. NRG Oncology seeks to improve the lives of cancer patients by conducting practice-changing multi-institutional clinical and translational research with emphases on gender-specific malignancies including gynecologic, breast and prostate cancers and on localized or locally advanced cancers of all types. Gilbert Padula, M.D., serves on the Publications, Cancer Prevention and Control and Cancer Care Delivery Research committees. In addition, he is study co-chair of NRG-CC007CD, Increasing the dose of survivorship care planning in prostate cancer survivors who receive androgen deprivation therapy, which was approved by the National Cancer Institute (NCI) Central Institutional Review Board (CIRB).
Alitto AR, Mantini G, Siepe G, Buwenge M, Nguyen N, Farioli A, Schiavina R, Catucci F, Deodato F, Fionda B, Frascino V, Macchia G, Padula GDA, Arcelli A, Cammelli S, Zanirato Rambaldi G, Cilia S. Valentini V, and Morganti AG. Tailored postoperative treatment of prostate cancer:final results of a phase 1/11 trial. Prostate Cancer and Prostatic Diseases. ePub ahead of print July 23, 2018
Karen Gil, Ph.D., Scientifc Director for Summa Health, served on the Quality of Life Committee.
Breast Cancer Program National Accreditation Program for Breast Cancers The Summa Health Breast Program at Summa Health System – Akron and Barberton Campuses has been granted a threeyear/full accreditation designation by the National Accreditation Program for Breast Centers (NAPBC), a program administered by the American College of Surgeons. Accreditation by the NAPBC is only given to those centers that have voluntarily committed to provide the highest level of quality breast care and that undergo a rigorous evaluation process and review of their performance.
11 11
Summa Health Staging & NCCN Guideline Study Summary (S4.6) 2018 Evaluation
Physician Reviewer: Dr. Eric Espinal Cancer Registry Reviewer: Melissa Smith, RHIT, CTR Each year, a physician member of the cancer committee performs a study to assess whether patients within the program are evaluated and treated according to evidencebased national treatment guidelines. The study must determine that the treatment plan is concordant with a recognized guideline. Study Topic: Evaluate accuracy of staging and treatment according to national guidelines for all 2017 small cell lung cancer cases.
Study Data: A report was generated from the cancer registry database to identify all 2017 small cell lung cancer cases, clinical stage, pathologic stage and treatment administered. A review of cases was completed to ensure the AJCC stage is documented and the NCCN Cancer Treatment Guidelines were followed. All of the 2017 analytic small cell lung cancer cases were reviewed. There were 37 cases identified from both the Akron and Barberton Campuses. Assessment: Staging Documentation and Accuracy: The abstract for each case was reviewed for accuracy of documentation in the cancer registry. In addition, the physician reviewer reviewed each case for staging accuracy. One case had to be reviewed in the cancer registry database for inaccuracy of the documented stage. The registrar had incorrectly documented the T clinical stage as a T2 instead of T4. The stage was corrected in the abstract.
Summary Item
Number of Patients
Percentage (%)
Goal
Total Cases Included in Review
37
100%
100% of the analytic small cell lung cancer cases
Staging Accuracy
36/37
97%
90% accuracy rate
Cases with Appropriate Treatment
37/37
100%
90% compliance with national treatment guidelines
Cases Reviewed for Missing Treatment: Cases Category Needing to Review Review
Reason for Review
Summary of Review
Were the issues resolved? Yes or No
17/181
Chemotherapy/ Radiation/PCI
No chemotherapy, radiation to primary site, or PCI documented in the abstract.
Patient received treatment elsewhere. Contacted the cancer registry at the outside facility for all treatment, including chemo, RT to lung, and PCI.
Yes – Case updated before being sent to physician reviewer.
17/1664
Chemotherapy/ Radiation/PCI
No PCI documented in the abstract.
Patient received PCI after completing concurrent chemoradiation. Abstract updated.
Yes
17/547
Chemotherapy/ Radiation/PCI
No PCI documented in the abstract.
Patient refused PCI.
Yes
17/676
Chemotherapy/ Radiation/PCI
No PCI documented in the abstract.
Patient refused PCI
Yes
17/1427
Chemotherapy/ Radiation/PCI
No PCI documented in the abstract.
Patient received PCI after completing concurrent chemoradiation. Abstract updated.
Yes
17/1691
Chemotherapy/ Radiation/PCI
No PCI documented in the abstract.
Patient received PCI after completing concurrent chemoradiation. Abstract updated.
Yes
Cases Reviewed for Staging Discrepancies: Cases Category Needing to Review Review
Reason for Review
17/802
Clinical T stage should be T4 Abstract reviewed and corrected to instead of T2, per medical T4, which makes the Stage Group oncologist’s progress notes IIIB instead of IIA. and cancer staging form. Stage Group should be IIIB.
AJCC clinical T stage
Summary of Review
Were the issues resolved? Yes or No Yes
Treatment According to NCCN Guidelines: Review of the 37 cases revealed that all 37 of the cases had the appropriate treatment documented within the abstract after additional review.
12
Cancer Institute 2018 Outcomes Report
13
Cooper Cancer Center Pharmacy Time Study (Lean Six Sigma Green Belt Project)
Research Update The SHCRC is committed to providing new and innovative treatments to our cancer patients, which include DOM-INNATE, an oral mucositis prevention trial, that was activated in 2018. The goal of the trial is to test the efficacy of an investigational drug to prevent and/or reduce oral mucositis symptoms in head and neck cancer patients. Oral mucositis, a painful side effect of chemoradiation, causes difficulty eating, drinking and swallowing, as well as frequent unplanned chemoradiation treatment delays.
Author: Susanna Petiya, PharmD Background From May 2017 to August 2017, Cooper Cancer Center received complaints from infusion patients that chemotherapy is not available in a timely fashion. Performance was measured and indicated a median of 46 minutes, mean of 53.9 minutes and standard deviation of 29.5 minutes.
Data Guidelines/Benchmarks Subsequent control data was compared to initial benchmark time that was obtained in September 2017.
Methodology/Criteria Lean Six Sigma tools were utilized to define the problem and measure. Methods included: SIPOC analysis, voice of the customer, capability analysis, process mapping, boxplots, correlation, brainstorming, and time stamp documentation.
Quality Improvement Implemented No identified opportunities for improvement were found within pharmacy operations. Future projects could utilize this data as a starting point. Control data was collected in July, August and September 2018. Further control data will be obtained.
Data Guidelines/Benchmarks To decrease the mean pharmacy preparation wait time to 30 minutes to initiate chemotherapy infusions.
Data reviewed by Cancer Committee on: 11/14/18
Analysis of Study Findings and Results 37.4 minutes of the 53.9 minutes is attributed to pharmacy preparation and nursing pickup time. The average pharmacy time from release of the order to awaiting pickup by nursing staff is 26.9 minutes. Pharmacy metrics studied included: the number of vials of medication necessary for the dose, if powder medication had an impact on preparation time, time of the day, day of the week. The metrics indicated that the number of vials as well as a powder medication, time of the day and day of the week did not influence the preparation time.
Data/Study reviewed/monitored by Quality Improvement Coordinator on: 11/6/18
Action Plan Control plan included once monthly data collection to compare to baseline data. Pictured above are the Oncology Summa Health Clinical Research Center Staff and physicians investigators: Sameer Mahesh, M.D. (medical oncology) and Bradley Clifford, M.D. (medical oncology). Not pictured: Desiree Doncals, M.D. (radiation oncology), Stephen Andrews, M.D. (gynecological oncology), Anand Desai, M.D. (radiation oncology)
Data reviewed by Medical Staff on: 1/10/19 The Summa Health Clinical Research Center (SHCRC) consists of dedicated nurses, coordinators and administrative support for research at Summa Health. The SHCRC staff are integrated as part of the oncology patient’s multidisciplinary team starting at diagnosis. This allows the healthcare team the opportunity to offer more treatment options through clinical trials to patients at any time during their cancer journey. Patients participating in research have the opportunity to receive the most innovative treatment options currently available. The SHCRC offers trials for the treatment and prevention of cancer, as well as the management of side effects related to cancer treatment. The majority of trials within the SHCRC focus on the cancer disease sites seen most often in our local patient population.
The Summa Health Clinical Research Center also collaborates with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to personalize and optimize cancer care. Through trials like Beating Lung Cancer in Ohio (BLCIO) and the Ohio Prevention and Treatment of Endometrial Cancer Initiative (OPTEC), both funded by Pelotonia, a grassroots cycling event held annually in Columbus that benefits the OSUCCC – James, our patients are offered the opportunity to be included in important research to improve cancer patient survival while receiving personalized test results and individualized care. Together with our patients, the oncology physicians and SHCRC staff are dedicated to moving cancer care forward.
Trials by Disease Site Other
16%
Breast
20% Colorectal
5%
Lung
11%
Gynecologic
19% Anand Desai, M.D. became PI of the DOM-INNATE study, sponsored by Soligenix, in January 2018.
Head and Neck
9%
Prostate
20%
14
Cancer Institute 2018 Outcomes Report
15
Free Skin Cancer Screening Community Event In support of National Skin Cancer Awareness Month, Summa Health held a free community event on May 19, 2018. Dermatologists were on hand for a free rapid skin exam and to provide cancer prevention tips. One in every five Americans will develop skin cancer by the age of 70, but routine checkups by a board-certified dermatologist or physician can help prevent a diagnosis. Fifty people attended the event, with more than half (26) referred for a referral/biopsy. These individuals were referred for:
Mole 7 Melanoma 5 Dysplastic Nevus 4 Basal Cell 3 Actinic Keratosis 1 Other 6 Total
26
Of the 50 attendees: • 10% of patients had a history of skin cancer • #1 reason attended the event: have a spot concerned about (58% of patients) • 22% always wear sunscreen • 62% had exposure to indoor tanning
Events like the free community event will help diagnose and treat patients sooner for skin cancers.
16
Cancer Institute 2018 Outcomes Report
Monitoring of Prevention, Screening and Outreach Activities
2018 Melanoma Cases at Summa Health Race
Number
Percentage
White
35
97.20%
Black
1
2.80%
Total
36
100%
2018 Prevention Programs: Plant-Based Diet: The Cancer Fighters in Our Food
2018 Melanoma Cases at Summa Health Age
Number
Percentage
20-29
1
2.80%
30-39
1
2.80%
40-49
5
13.90%
50-59
2
5.50%
60-69
11
30.60%
70-79
11
30.60%
80-89
3
8.30%
90+
2
5.50%
Total
100%
39% of the cases were late stage disease (Stage III and IV).
Ongoing Program Cancer Target: Solid Tumors Participants: 63 (29 participants in 2017)
Year-To-Date Results Increase in Awareness
Evidence-based Guideline: American Institute for Cancer Research Summary: Recent research has shown several benefits to a plant-based diet. Plants, particularly raw plants, are rich in vitamins, providing more energy and aiding digestion. More research suggests diets loaded with fruits and vegetables can help prevent cancer, diabetes, heart disease and lower blood pressure. We offered a monthly nutrition class focused on a plant-based diet. The goal was to increase knowledge to encourage healthy lifestyle changes and how to transition to a plant-based diet to help prevent a cancer diagnosis or recurrence. Classes will continue be offered monthly at the Jean & Milton Cooper Pavilion and bimonthly at Parkview Pavilion.
27%
21% 19% 17%
6%
Q1
Q2
Q3
Q4
Q5
17
Committee Members Outcomes Report Project Committee
Franciska Kiraly, M.D.
Summa Health Leadership
Donna Burson Corporate Communications Strategist
Joseph Koenig, M.D.
T. Clifford Deveny, M.D. President and Chief Executive Officer
Sandy Kohut, RRT, BSA
Tracy Mondello, MS, CIM Program Coordinator, Clinical Research
Kari Kovach, RN, BSN, CBCN
Lesley Richard Senior Marketing Strategist
Robin Laskey, M.D.
Barb Saylor, MSN, RN System Director, Oncology Service Line Melissa Smith, RHIT, CTR Program Coordinator, Cancer Registry Christina White, BS Manager, Support and Family Programs
Tiffany Kurtz, BSN, RN, OCN
Melanie Lynch, M.D. Alisa Mahan-Zeitz American Cancer Society Sameer Mahesh, M.D. Quality Improvement Coordinator Jessica Moeller, Ph.D. Psychosocial Services Coordinator
Cancer Committee Members
Joshua Nething, M.D.
Kathleen Allen, M.D.
Sue Newbrough, BSN, RN
Stephen Andrews, M.D.
Tami O’Connor, PTA, CLT
Brian Bauman, M.D.
Sally Olszewski, BSN, RN
Karen Bochert, BSN, RN Nicole Buie, RN
Gilbert Padula, M.D. Chair
Bradley Clifford, M.D.
Leslie Pfaff
Arthur Dalton, M.D.
Susan Popovici, LISW-S
Joseph Dankoff, M.D.
Jim Posendek, RPh
Evan Deighan, MSN, RN, CMSRN
Connie Reece, MSN, RN
Anand Desai, M.D.
Kathleen Robinson, RPh, BCOP
Desiree Doncals, M.D.
Rella Rotondo, RD, LD
Jeanette Doria, BS
Barb Saylor, MSN, RN
Felicia Edwards, MSN, RN
Frederick Slezak, M.D.
Jennifer Eaton, Ph.D., CHRC Clinical Research Coordinator
Melissa Smith, RHIT, CTR Cancer Registry Quality Coordinator
Eric Espinal, M.D.
Shannon Speaks, LISW, MSSA
Heidi Eve-Cahoon, MSN, CNP
Margaret Sweigert, RN, MBA
Elise Evey, BSN, RN
Leann Tanaskovic, RHIT, CTR
Jacelyn Fitzwater, BSN, RN-BC, OCN
Ellen Walker, PT, CLT
John Fondran, M.D.
Christina White, BS Community Outreach Coordinator
Andrew Haas, M.D. Cherie Hart-Spicer, M.D. Cancer Liaison Physician
David Custodio, M.D. President, Akron and St. Thomas Campuses Michael Hughes, M.D. President, Barberton Campus Tammy Scarborough, MBA President, Ambulatory Care and Clinical Service Lines Margaret Sweigert, RN, MBA Vice President, Service lines/Ambulatory Operations Gilbert Padula, M.D. Medical Director, Oncology Service Line Desiree Doncals, M.D. Medical Director, Radiation Oncology Sameer Mahesh, M.D. Medical Director, Hematology Oncology and Oncology Care Model Barb Saylor, MSN, RN System Director, Oncology Service Line
Ashley Wyatt, CNP, MS, BSN, RN
John Jakob, M.D. Cindy Jones, RN, BSN, OCN, CTTS Cancer Conference Coordinator Lauren Kinsell, M.D.
18
Cancer Institute 2018 Outcomes Report
19
For more information, visit summahealth.org/cancer or call 800.237.8662. CAN-19-42465/CS/KG/8-19